CRL
Price
$206.54
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
89 days until earnings call
HBIO
Price
$2.17
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
111 days until earnings call
Ad is loading...

CRL vs HBIO

Header iconCRL vs HBIO Comparison
Open Charts CRL vs HBIOBanner chart's image
Charles River Laboratories International
Price$206.54
Change-$0.00 (-0.00%)
Volume$981.96K
CapitalizationN/A
Harvard Bioscience
Price$2.17
Change-$0.00 (-0.00%)
Volume$211.37K
CapitalizationN/A
CRL vs HBIO Comparison Chart
Loading...
CRL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CRL vs. HBIO commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRL is a StrongBuy and HBIO is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (CRL: $206.54 vs. HBIO: $2.17)
Brand notoriety: CRL and HBIO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CRL: 135% vs. HBIO: 168%
Market capitalization -- CRL: $13.96B vs. HBIO: $184.01M
CRL [@Medical Specialties] is valued at $13.96B. HBIO’s [@Medical Specialties] market capitalization is $184.01M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRL’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).

  • CRL’s FA Score: 0 green, 5 red.
  • HBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, CRL is a better buy in the long-term than HBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRL’s TA Score shows that 5 TA indicator(s) are bullish while HBIO’s TA Score has 2 bullish TA indicator(s).

  • CRL’s TA Score: 5 bullish, 5 bearish.
  • HBIO’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CRL is a better buy in the short-term than HBIO.

Price Growth

CRL (@Medical Specialties) experienced а -3.58% price change this week, while HBIO (@Medical Specialties) price change was -23.05% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.22%. For the same industry, the average monthly price growth was +0.64%, and the average quarterly price growth was +2.87%.

Reported Earning Dates

CRL is expected to report earnings on Feb 12, 2025.

HBIO is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Medical Specialties (-2.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRL($14B) has a higher market cap than HBIO($184M). CRL YTD gains are higher at: -12.631 vs. HBIO (-59.439). CRL has higher annual earnings (EBITDA): 1.03B vs. HBIO (8.03M). CRL has more cash in the bank: 277M vs. HBIO (4.28M). HBIO has less debt than CRL: HBIO (42.8M) vs CRL (3.07B). CRL has higher revenues than HBIO: CRL (4.13B) vs HBIO (112M).
CRLHBIOCRL / HBIO
Capitalization14B184M7,609%
EBITDA1.03B8.03M12,847%
Gain YTD-12.631-59.43921%
P/E Ratio29.15N/A-
Revenue4.13B112M3,687%
Total Cash277M4.28M6,467%
Total Debt3.07B42.8M7,164%
FUNDAMENTALS RATINGS
CRL vs HBIO: Fundamental Ratings
CRL
HBIO
OUTLOOK RATING
1..100
93
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
5891
PRICE GROWTH RATING
1..100
4686
P/E GROWTH RATING
1..100
342
SEASONALITY SCORE
1..100
4850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRL's Valuation (77) in the Miscellaneous Commercial Services industry is in the same range as HBIO (99) in the Biotechnology industry. This means that CRL’s stock grew similarly to HBIO’s over the last 12 months.

CRL's Profit vs Risk Rating (72) in the Miscellaneous Commercial Services industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CRL’s stock grew similarly to HBIO’s over the last 12 months.

CRL's SMR Rating (58) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for HBIO (91) in the Biotechnology industry. This means that CRL’s stock grew somewhat faster than HBIO’s over the last 12 months.

CRL's Price Growth Rating (46) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for HBIO (86) in the Biotechnology industry. This means that CRL’s stock grew somewhat faster than HBIO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is in the same range as CRL (34) in the Miscellaneous Commercial Services industry. This means that HBIO’s stock grew similarly to CRL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLHBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 9 days ago
0%
Declines
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
CRL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X90584.1640002628.351600
+2.99%
Bitcoin cryptocurrency
TSLA330.241.75
+0.53%
Tesla
AAPL225.120.89
+0.40%
Apple
SPY597.190.29
+0.05%
SPDR® S&P 500® ETF Trust
GME26.46-0.38
-1.42%
GameStop Corp

CRL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRL
1D Price
Change %
CRL100%
-4.35%
IQV - CRL
73%
Closely correlated
-0.96%
CTKB - CRL
61%
Loosely correlated
-3.69%
ICLR - CRL
58%
Loosely correlated
-3.94%
AZTA - CRL
57%
Loosely correlated
-3.22%
MEDP - CRL
53%
Loosely correlated
+0.31%
More

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with CTKB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then CTKB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-4.82%
CTKB - HBIO
49%
Loosely correlated
-3.69%
CRL - HBIO
44%
Loosely correlated
-4.35%
KIDS - HBIO
43%
Loosely correlated
+0.92%
ANGO - HBIO
43%
Loosely correlated
-2.10%
ICUI - HBIO
41%
Loosely correlated
-1.80%
More